Corynebacterium glutamicum mutant with improved L-lysine production ability and method for producing L-lysine using the same

By introducing targeted amino acid substitutions in the gapA gene of Corynebacterium glutamicum, the strain's glyceraldehyde 3-phosphate dehydrogenase activity is enhanced, leading to a significant increase in L-lysine production.

JP2024544690AActive Publication Date: 2024-12-03DAESANG CORP
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024533878
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-06
Filing Date
2022-07-29
Publication Date
2024-12-03
Estimated Expiration
2042-07-29

AI Technical Summary

Technical Problem

Existing methods for enhancing L-lysine production in Corynebacterium glutamicum strains do not effectively address the potential of glyceraldehyde 3-phosphate dehydrogenase in improving lysine biosynthesis pathways.

Method used

Introduce specific amino acid substitutions in the gapA gene encoding glyceraldehyde 3-phosphate dehydrogenase to enhance its activity, specifically altering amino acids at positions 36 and 37 to serine and threonine, and 100th to valine, respectively, to increase NADPH production for improved lysine biosynthesis.

Benefits of technology

The modified Corynebacterium glutamicum strain exhibits a 5-20% increase in L-lysine production, reaching yields of 70-85g/L, by optimizing glyceraldehyde 3-phosphate dehydrogenase activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544690000001_ABST
    Figure 2024544690000001_ABST
Patent Text Reader

Abstract

The present invention relates to a Corynebacterium glutamicum mutant having improved L-lysine-producing ability and a method for producing L-lysine using the same. The Corynebacterium glutamicum mutant has an amino acid mutation induced in a gene encoding glyceraldehyde-3-phosphate dehydrogenase, and thus the enzyme activity is improved, thereby improving the L-lysine production yield.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a Corynebacterium glutamicum mutant having improved L-lysine-producing ability and a method for producing L-lysine using the same. [Background technology]

[0002] L-lysine is an essential amino acid that cannot be synthesized in the human or animal body and must be supplied from the outside. It is generally produced by fermentation using microorganisms such as bacteria and yeast. L-lysine can be produced by using wild-type strains obtained in natural conditions or mutant strains modified to improve L-lysine production ability. Recently, in order to improve the efficiency of L-lysine production, various recombinant strains or mutant strains with excellent L-lysine production ability and methods for producing L-lysine using the same have been developed by applying recombinant gene technology to microorganisms such as Escherichia coli and Corynebacterium, which are often used to produce L-amino acids and other useful substances.

[0003] According to Korean Patent Registration Nos. 10-0838038 and 10-2139806, L-lysine production ability can be improved by changing the base sequence or amino acid sequence of a gene encoding a protein including an enzyme related to L-lysine production to increase the expression of the gene or by removing unnecessary genes. In addition, Korean Patent Publication No. 10-2020-0026881 discloses a method for changing an existing promoter of a gene to a promoter having strong activity in order to increase the expression of a gene encoding an enzyme involved in L-lysine production.

[0004] As described above, various methods for increasing L-lysine productivity have been developed. However, since there are several tens of types of proteins, such as enzymes, transcription factors, and transport proteins, which are directly and indirectly related to L-lysine production, there is still much research to be done to determine whether L-lysine productivity is increased by changing the activity of these proteins. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Korean Patent No. 10-0838038 [Patent Document 2] Korean Patent No. 10-2139806 [Patent Document 3] Korean Patent Publication No. 10-2020-0026881 Summary of the Invention [Problem to be solved by the invention]

[0006] An object of the present invention is to provide a Corynebacterium glutamicum mutant strain having improved L-lysine-producing ability.

[0007] Another object of the present invention is to provide a method for producing L-lysine using the mutant strain. [Means for solving the problem]

[0008] The present inventors conducted research to develop a new mutant strain having improved L-lysine production ability using a Corynebacterium glutamicum strain, and as a result, they confirmed that L-lysine production amount increases when an amino acid at a specific position in the amino acid sequence of the gapA gene encoding glyceraldehyde-3-phosphate dehydrogenase involved in the L-lysine biosynthesis pathway is substituted, thereby completing the present invention.

[0009] One aspect of the present invention provides a Corynebacterium glutamicum mutant having improved L-lysine productivity due to improved glyceraldehyde-3-phosphate dehydrogenase activity.

[0010] "Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)" as used in the present invention refers to an enzyme involved in glycolysis or glycosynthesis in energy metabolism, which catalyzes the reversible reaction of glyceraldehyde 3-phosphate and 1,3-bisphosphoglycerate, while reducing the coenzyme NAD+ or NADP+ to NADH or NADPH, or oxidizing it. GAPDH is divided into three subtypes, GapA, GapB, and GapN, depending on the type of coenzyme. GapA catalyzes the production of 1,3-bisphosphoglycerate and NADH from glyceraldehyde-3-phosphate using NAD during glycolysis, as well as the production of 1,3-bisphosphoglycerate using NADH during gluconeogenesis, while GapB is activated by both NAD and NADP and acts only in gluconeogenesis. GapN is NADP-dependent and catalyzes the irreversible oxidation of glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate without the generation of ATP.

[0011] In the present invention, in order to produce or supply a large amount of NADPH required for the lysine biosynthesis process, a mutant strain was prepared in which GapA activity was improved and NADPH was produced using NADP instead of NAD in the conversion of glyceraldehyde 3-phosphate.

[0012] According to one embodiment of the present invention, the glyceraldehyde 3-phosphate dehydrogenase may be GapA.

[0013] According to one embodiment of the present invention, the glyceraldehyde-3-phosphate dehydrogenase may be derived from a strain of the genus Corynebacterium. Specifically, the Corynebacterium genus strains include Corynebacterium glutamicum, Corynebacterium crudilactis, Corynebacterium deserti, Corynebacterium callunae, Corynebacterium suranareeae, Corynebacterium lubricantis, Corynebacterium doosanense, Corynebacterium efficiens, Corynebacterium uteri, Corynebacterium uterikii, Corynebacterium spp. Corynebacterium uterequi, Corynebacterium stationis, Corynebacterium pacaense, Corynebacterium singulare, Corynebacterium humireducens, Corynebacterium marinum, Corynebacterium halotolerans, Corynebacterium spheniscorum, Corynebacterium freiburgense, Corynebacterium striatum striatum, Corynebacterium canis, Corynebacterium ammoniagenesammoniagenes, Corynebacterium renale, Corynebacterium pollutisoli, Corynebacterium imitans, Corynebacterium caspium, Corynebacterium testudinoris, Corynebacterium pseudopelargi, or Corynebacterium flavescens, but is not limited thereto.

[0014] The term "improved activity" used in the present invention means that a protein such as a target enzyme, transcription factor, transport protein, etc. is structurally modified to produce a product or protein complex different from that of a wild-type strain or a strain before modification, or the concentration of a product or protein complex is increased compared to that of a wild-type strain or a strain before modification. Here, structural modification refers to a physical change in a reactive site of a protein for a substrate or a binding protein, for example, an active site of an enzyme. Such improvement in activity includes a case where the activity of the protein itself is different from or increased compared to the activity of the protein originally possessed by a microorganism due to nucleotide substitution, insertion, deletion, or a combination thereof in a gene encoding the protein, and a case where the overall enzyme activity level in a cell is higher than that of a wild-type strain or a strain before modification due to increased expression or translation of a gene encoding the protein, etc., and a combination of these.

[0015] According to a specific embodiment of the present invention, the improvement of the activity of glyceraldehyde-3-phosphate dehydrogenase may be achieved by inducing site-specific mutagenesis in a gene encoding glyceraldehyde-3-phosphate dehydrogenase.

[0016] According to one embodiment of the present invention, the gene encoding glyceraldehyde 3-phosphate dehydrogenase may be represented by the amino acid sequence of SEQ ID NO:1.

[0017] According to a specific example of the present invention, the gene encoding glyceraldehyde 3-phosphate dehydrogenase may be represented by the base sequence of SEQ ID NO:2.

[0018] According to one embodiment of the present invention, the improvement in the activity of glyceraldehyde-3-phosphate dehydrogenase may be achieved by substituting one or more amino acids in the region of amino acids 10 to 130 in the amino acid sequence of a gene encoding glyceraldehyde-3-phosphate dehydrogenase.

[0019] More specifically, the genetic mutation in the present invention may be a continuous or discontinuous substitution of one or more amino acids in the region of amino acids 10 to 130, preferably one, two, three, four, or five amino acids in the region of amino acids 20 to 120, 30 to 110, 30 to 50, or 90 to 110.

[0020] According to one embodiment of the present invention, the improvement in the activity of glyceraldehyde-3-phosphate dehydrogenase may be achieved by substituting one or more of the amino acids at positions 36, 37, and 100 in the amino acid sequence of a gene encoding glyceraldehyde-3-phosphate dehydrogenase.

[0021] According to one embodiment of the present invention, a Corynebacterium glutamicum mutant having a new amino acid sequence of the gapA gene encoding glyceraldehyde-3-phosphate dehydrogenase of a Corynebacterium glutamicum strain was obtained by substituting leucine (Leu) at the 36th site with serine (Ser) and threonine (Thr) at the 37th site with lysine (Lys). Such a Corynebacterium glutamicum mutant may contain the gapA gene represented by the amino acid sequence of SEQ ID NO:3.

[0022] According to one embodiment of the present invention, a Corynebacterium glutamicum mutant having a new amino acid sequence of the gapA gene encoding glyceraldehyde-3-phosphate dehydrogenase of the Corynebacterium glutamicum strain was obtained by substituting leucine (Leu) with serine (Ser) at the 36th site, threonine (Thr) with lysine (Lys) at the 37th site, and phenylalanine (Phe) with valine (Val) at the 100th site in the amino acid sequence of the gapA gene encoding glyceraldehyde-3-phosphate dehydrogenase of the Corynebacterium glutamicum strain. Such a Corynebacterium glutamicum mutant may contain the gapA gene represented by the amino acid sequence of SEQ ID NO:5.

[0023] Thus, a Corynebacterium glutamicum mutant having a mutation in the glyceraldehyde 3-phosphate dehydrogenase gene or the amino acid sequence encoding it can improve L-lysine production ability.

[0024] As used herein, "improved production ability" means that L-lysine productivity is increased compared to that of a parent strain. The parent strain refers to a wild-type or mutant strain that is the subject of mutation, and includes a strain that is the subject of direct mutation or that is transformed with a recombinant vector, etc. In the present invention, the parent strain may be a wild-type Corynebacterium glutamicum strain or a strain mutated from the wild-type.

[0025] According to one embodiment of the present invention, the parent strain may be a Corynebacterium glutamicum strain (Korean Patent Application No. 10-2021-0050318) (hereinafter referred to as "Corynebacterium glutamicum DS2 strain") having weakened activity of citrate synthase involved in the lysine biosynthesis pathway.

[0026] According to one embodiment of the present invention, the Corynebacterium glutamicum mutant strain having improved L-lysine productivity contains an amino acid mutation in the gapA gene encoding glyceraldehyde-3-phosphate dehydrogenase, thereby increasing the supply of NADPH required for L-lysine biosynthesis and exhibiting increased L-lysine productivity compared to the parent strain. In particular, the L-lysine production amount is increased by 5% or more, specifically 5 to 20%, compared to the parent strain, and the mutant strain can produce 70 g or more, specifically 70 to 85 g of L-lysine per 1 L of the strain culture solution.

[0027] According to one embodiment of the present invention, a Corynebacterium glutamicum mutant can be produced by a recombinant vector containing a mutant in which the amino acid sequence of the gapA gene encoding glyceraldehyde-3-phosphate dehydrogenase is partially replaced in a parent strain.

[0028] As used herein, the term "part" means not the entire amino acid sequence, base sequence, or polynucleotide sequence, and may be, but is not limited to, 1 to 300 residues, preferably 1 to 100 residues, and more preferably 1 to 50 residues.

[0029] The term "mutant" as used herein means a mutant in which one or more amino acids have been substituted in the region of amino acids 10 to 130 in the amino acid sequence of the glyceraldehyde 3-phosphate dehydrogenase gene involved in the biosynthesis of L-lysine.

[0030] According to one embodiment of the present invention, the mutant in which the 36th and 37th amino acids in the amino acid sequence of the glyceraldehyde 3-phosphate dehydrogenase gene are substituted may have the amino acid sequence of SEQ ID NO: 3 or the base sequence of SEQ ID NO: 4.

[0031] According to one embodiment of the present invention, the mutant in which the 36th, 37th, and 100th amino acids in the amino acid sequence of the glyceraldehyde-3-phosphate dehydrogenase gene are substituted may have the amino acid sequence of SEQ ID NO:5 or the base sequence of SEQ ID NO:6.

[0032] The term "vector" as used herein refers to an expression vector capable of expressing a target protein in a suitable host cell, and a gene construct containing the necessary regulatory elements operably linked to express a gene insert. Here, "operably linked" means that a gene to be expressed and its regulatory sequence are linked in a manner that allows the gene to be expressed by functionally linking them to each other, and "regulatory elements" include a promoter for transcription, an optional operator sequence for regulating transcription, a sequence encoding a suitable mRNA ribosome binding site, and a sequence for regulating the termination of transcription and translation. Such vectors include, but are not limited to, plasmid vectors, cosmid vectors, bacteriophage vectors, and virus vectors.

[0033] The "recombinant vector" used in the present invention is capable of replicating independently of the genome of a host cell after being transformed into the host cell, or is sewn into the genome itself. In this case, the "suitable host cell" is one in which the vector can replicate and includes a replication origin, which is a specific base sequence from which replication is initiated.

[0034] The transformation can be carried out by selecting a suitable vector introduction technique depending on the host cell, so that the gene of interest can be expressed in the host cell. For example, the vector can be introduced by electroporation, heat shock, calcium phosphate (CaPO4) precipitation, calcium chloride (CaCl2) precipitation, microinjection, polyethylene glycol (PEG) method, DEAE-dextran method, cationic liposome method, lithium acetate-DMSO method, or a combination thereof. The transformed gene can be expressed in the host cell, and can be inserted into the host cell chromosome or located extrachromosomally, without limitation.

[0035] The host cell includes cells that have been transfected, transformed or infected in vivo or in vitro with a recombinant vector or polynucleotide of the invention. A host cell containing a recombinant vector of the invention may be a recombinant host cell, recombinant cell or recombinant microorganism.

[0036] In addition, the recombinant vector according to the present invention may contain a selection marker, which is used to select a transformant (host cell) transformed with the vector, and since only cells expressing the selection marker can survive in a medium treated with the selection marker, it is possible to select transformed cells. Representative examples of the selection marker include, but are not limited to, kanamycin, streptomycin, and chloramphenicol.

[0037] The gene inserted into the recombinant vector for transformation of the present invention is replaced in a host cell such as a microorganism of the genus Corynebacterium by homologous recombination crossing over.

[0038] According to one embodiment of the present invention, the host cell may be a Corynebacterium strain, for example the Corynebacterium glutamicum strain DS2.

[0039] Another aspect of the present invention provides a method for producing L-lysine, comprising: a) culturing the Corynebacterium glutamicum mutant in a medium; and b) recovering L-lysine from the mutant or the medium in which the mutant is cultured.

[0040] The culture may be performed using a suitable medium and culture conditions known in the art, and a person skilled in the art can easily adjust the medium and culture conditions for use. Specifically, the medium may be a liquid medium, but is not limited thereto. The culture method may include, but is not limited to, for example, batch culture, continuous culture, fed-batch culture, or a combination thereof.

[0041] According to one embodiment of the present invention, the medium should meet the requirements of a specific strain in an appropriate manner, and can be modified by a person skilled in the art. Culture media for Corynebacterium strains can be found in the literature (Manual of Methods for General Bacteriology, American Society for Bacteriology, Washington DC, USA, 1981), but are not limited thereto.

[0042] According to one embodiment of the present invention, the medium may contain a variety of carbon sources, nitrogen sources and trace element components. Usable carbon sources include sugars and carbohydrates such as glucose, sucrose, lactose, fructose, maltose, starch, cellulose, oils and fats such as soybean oil, sunflower oil, castor oil, coconut oil, etc., fatty acids such as palmitic acid, stearic acid, linoleic acid, alcohols such as glycerol, ethanol, organic acids such as acetic acid. These substances may be used individually or as mixtures, but are not limited to these. Usable nitrogen sources include peptone, yeast extract, meat juice, malt extract, corn steep liquor, soybean malt and urea, or inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate. Nitrogen sources may also be used individually or as mixtures, but are not limited to these. Usable phosphorus sources may include, but are not limited to, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts. The culture medium may also contain metal salts necessary for growth, such as magnesium sulfate or iron sulfate, but is not limited thereto. Other essential growth substances, such as amino acids and vitamins, may also be included. Furthermore, suitable precursors can be used for the culture medium. The medium or individual components are added to the culture solution in a suitable manner during the culture process, either batchwise or continuously, but is not limited thereto.

[0043] According to a specific embodiment of the present invention, the pH of the culture solution can be adjusted by adding compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid and sulfuric acid to the microorganism culture solution in an appropriate manner during the culture. In addition, the generation of bubbles can be suppressed using an antifoaming agent such as fatty acid polyglycol ester during the culture. Additionally, oxygen or an oxygen-containing gas (e.g., air) can be injected into the culture solution to maintain the aerobic state of the culture solution. The temperature of the culture solution can usually be 20°C to 45°C, for example, 25°C to 40°C. The culture period can be continued until a desired production amount of a useful substance is obtained, and can be, for example, 10 to 160 hours.

[0044] According to one embodiment of the present invention, the step of recovering L-lysine from the cultured mutant and the medium in which the mutant is cultured can be carried out by collecting or recovering the produced L-lysine from the medium using a suitable method known in the art depending on the culture method, such as, but not limited to, centrifugation, filtration, extraction, spraying, drying, evaporation, precipitation, crystallization, electrophoresis, differential dissolution (e.g., ammonium sulfate precipitation), and chromatography (e.g., ion exchange, affinity, hydrophobic, and size exclusion).

[0045] According to one embodiment of the present invention, the step of recovering lysine can be performed by centrifuging the culture medium at low speed to remove the biomass, and separating the resulting supernatant by ion exchange chromatography.

[0046] According to one embodiment of the present invention, the step of recovering L-lysine can include a process of purifying L-lysine. Effect of the Invention

[0047] In the Corynebacterium glutamicum mutant according to the present invention, amino acid mutations are induced in the gene encoding glyceraldehyde-3-phosphate dehydrogenase, improving the enzyme activity and thereby increasing the L-lysine production yield. [Brief description of the drawings]

[0048] [Figure 1] FIG. 2 shows the structure of the DS2-gapA-Pm1 vector containing the gapA gene in which the 36th amino acid in the amino acid sequence has been substituted from leucine to serine and the 37th amino acid in the amino acid sequence has been substituted from threonine to lysine according to one embodiment of the present invention. [Diagram 2]FIG. 1 shows the structure of the DS2-gapA-Pm2 vector containing the gapA gene in which the 36th amino acid in the amino acid sequence has been replaced from leucine to serine, the 37th amino acid has been replaced from threonine to lysine, and the 100th amino acid has been replaced from phenylalanine to valine according to one embodiment of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0049] The present invention will be described in more detail below. However, such description is merely presented as an example for understanding the present invention, and the scope of the present invention is not limited by such exemplary description.

[0050] Example 1. Preparation of Corynebacterium glutamicum mutant strains To generate mutant strains of Corynebacterium glutamicum with improved glyceraldehyde-3-phosphate dehydrogenase activity, Corynebacterium glutamicum DS2 and E. coli DH5a (HIT Competent Cells) were used as parent strains. TM , Cat No. RH618) was used.

[0051] The Corynebacterium glutamicum DS2 strain was cultured at 30°C in CM-broth medium (pH 6.8) containing 5 g glucose, 2.5 g NaCl, 5.0 g yeast extract, 1.0 g urea, 10.0 g polypeptone, and 5.0 g beef extract in 1 L of distilled water.

[0052] The E. coli DH5a was cultured at 37° C. on LB medium containing 10.0 g of tryptone, 10.0 g of NaCl, and 5.0 g of yeast extract in 1 L of distilled water.

[0053] The antibiotics kanamycin and streptomycin were manufactured by Sigma.

[0054] DNA sequencing analysis was performed by Macrogen Corporation.

[0055] 1-1. Construction of recombinant vector In order to increase the supply of NADPH required for lysine biosynthesis and increase L-lysine productivity, the activity of glyceraldehyde-3-phosphate dehydrogenase was improved to produce NADPH instead of NADH. In the method used in this example, specific mutations were induced in the gapA gene encoding glyceraldehyde-3-phosphate dehydrogenase. The 36th amino acid in the amino acid sequence of the gapA gene was replaced from leucine to serine, and the 37th amino acid was replaced from threonine to lysine. The 442 bp left arm and 552 bp right arm were amplified by PCR from the portion including the 36th and 37th amino acids of the gapA gene on the Corynebacterium glutamicum genome, and then linked by overlap PCR, and cloned into the recombinant vector pCGI (see Kim et al., Journal of Microbiological Methods 84 (2011) 128-130). The plasmid was named DS2-gapA-Pm1 (see FIG. 1). The primers in Table 1 below were used to amplify each gene fragment to construct the plasmid.

[0056] [Table 1]

[0057] PCR was performed using the above primers under the following conditions. Using a Thermocycler (TP600, TAKARA BIO Inc., Japan), 100 μM of each deoxynucleotide triphosphate (dATP, dCTP, dGTP, dTTP) was added to the reaction solution, and 25 to 30 cycles were performed in the presence of 1 unit of pfu-X DNA polymerase mixture (Solgent) using 1 pM of oligonucleotide and 10 ng of chromosomal DNA of Corynebacterium glutamicum ATCC13032 as a template. PCR was performed under the following conditions: (i) denaturation step: 94°C for 30 seconds, (ii) annealing step: 58°C for 30 seconds, and (iii) extension step: 72°C for 1 to 2 minutes (allowing 2 minutes of polymerization time per 1 kb).

[0058] The gene fragment thus prepared was cloned into the pCGI vector by self-assembly cloning. The vector was transformed into E. coli DH5a, spread on an LB-agar plate containing 50 μg / ml kanamycin, and cultured at 37°C for 24 hours. The finally formed colonies were isolated to confirm that the insert was correctly present in the vector, and the vector was isolated and used for recombination of Corynebacterium glutamicum strains.

[0059] A common process for the above methods was amplification of the gene of interest by PCR from the genomic DNA of Corynebacterium glutamicum ATCC13032, and inserting it into the pCGI vector by self-assembled cloning strategy, followed by selection from E. coli DH5a6. For chromosomal base substitution, the genes of each fragment were individually amplified, and the target DNA fragment was produced by overlap PCR. Ex Taq polymerase (Takara) and Pfu polymerase (Solgent) were used as PCR amplification enzymes for gene recombination, and various restriction enzymes and DNA modifying enzymes were NEB products, using the buffers and protocols provided.

[0060] 1-2. Production of mutant strains The DS2-gapA-Pm1 was used to prepare the mutant strain DS2-1. The vector was prepared so that the final concentration was 1 μg / μl or more, and the primary recombination was induced in the Corynebacterium glutamicum DS2 strain by electroporation (see Tauch et al., FEMS Microbiology letters 123 (1994) 343-347). The electroporated strain was then spread on a CM-agar plate containing 20 μg / μl kanamycin to separate colonies, and PCR and base sequence analysis were used to confirm whether the gene was properly inserted at the induced position on the genome. The strain thus isolated was inoculated into a CM-agar liquid medium containing streptomycin in order to induce the secondary recombination again, and cultured overnight or more, and then spread on an agar medium containing the same concentration of streptomycin to separate colonies. Finally, the isolated colonies were checked for resistance to kanamycin, and the strains without antibiotic resistance were examined by sequence analysis to see whether a mutation had been introduced into the gapA gene (see reference [Schafer et al., Gene 145 (1994) 69-73]). Finally, a Corynebacterium glutamicum mutant (DS2-1) with a mutant gapA gene was obtained.

[0061] Example 2. Preparation of Corynebacterium glutamicum mutants In order to increase the supply of NADPH required for lysine biosynthesis and increase L-lysine productivity, the activity of glyceraldehyde-3-phosphate dehydrogenase was improved to produce NADPH instead of NADH. In the method used in this example, specific mutations were induced in the gapA gene encoding glyceraldehyde-3-phosphate dehydrogenase. The 36th amino acid in the amino acid sequence of the gapA gene was replaced by serine instead of leucine, the 37th amino acid was replaced by lysine instead of threonine, and the 100th amino acid was replaced by valine instead of phenylalanine. The 442 bp part of the left arm and the 360 ​​bp part of the right arm were amplified by PCR from the part including the 36th, 37th, and 100th amino acids of the gapA gene on the Corynebacterium glutamicum genome, and then ligated by overlap PCR, followed by cloning into the recombinant vector pCGI (see reference [Kim et al., Journal of Microbiological Methods 84 (2011) 128-130]). The plasmid was named DS2-gapA-Pm2 (see FIG. 2). The primers in Table 2 below were used to amplify each gene fragment to construct the plasmid.

[0062] [Table 2]

[0063] Thereafter, the same method as in Example 1 was carried out to produce and obtain a mutant strain, DS2-2 strain, using the DS2-gapA-Pm2.

[0064] Experimental Example 1. Comparison of L-lysine productivity between parent and mutant strains The parent strain Corynebacterium glutamicum DS2 and the lysine-producing mutant strains DS2-1 and DS2-2 prepared in Examples 1 and 2 were compared in terms of L-lysine productivity.

[0065] Each strain was inoculated into a 100 ml flask containing 10 ml of a lysine medium having the composition shown in Table 3 below, and cultured with shaking at 180 rpm at 30° C. for 28 hours. After the culture was completed, the amount of L-lysine produced was measured by HPLC (Shimazu, Japan) for lysine analysis, and the results are shown in Table 4 below.

[0066] [Table 3]

[0067] [Table 4]

[0068] As shown in Table 4, in the Corynebacterium glutamicum mutants DS2-1 and DS2-2, specific positions (amino acids 36 and 37, or amino acids 36, 37, and 100) of the amino acid sequence of the gapA gene were substituted with optimal amino acid residues to enhance the lysine biosynthesis pathway, and it was confirmed that the L-lysine productivity was increased by about 12.5% ​​and 11.1%, respectively, compared to the parent strain Corynebacterium glutamicum DS2 strain. From this result, it was found that the gapA gene mutation improves the activity of glyceraldehyde 3-phosphate dehydrogenase, thereby improving the L-lysine production ability of the strain.

[0069] The present invention has been described above with a focus on its preferred embodiments. Those skilled in the art will understand that the present invention can be realized in modified forms without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered from an explanatory perspective, not a restrictive one. The scope of the present invention is defined in the claims, not the above description, and all differences within the scope of the equivalents should be interpreted as being included in the present invention.

Claims

1. A mutant strain of Corynebacterium glutamicum having improved L-lysine productivity due to improved glyceraldehyde 3-phosphate dehydrogenase activity.

2. The Corynebacterium glutamicum mutant according to claim 1, wherein the improvement of glyceraldehyde-3-phosphate dehydrogenase activity is achieved by inducing a site-specific mutation in a gene encoding glyceraldehyde-3-phosphate dehydrogenase.

3. The Corynebacterium glutamicum mutant according to claim 1, wherein the improvement in glyceraldehyde-3-phosphate dehydrogenase activity is achieved by substituting one or more of the 36th, 37th, and 100th amino acids in the amino acid sequence of a gene encoding glyceraldehyde-3-phosphate dehydrogenase.

4. The Corynebacterium glutamicum mutant strain according to claim 1 , wherein the mutant strain comprises an amino acid sequence represented by SEQ ID NO: 3 or 5.

5. a) culturing the mutant strain according to any one of claims 1 to 4 in a medium; and b) recovering L-lysine from the mutant strain or from the medium in which the mutant strain has been cultured.

Citation Information

Patent Citations

  • Modified glyceraldehyde-3-phosphate dehydrogenase from corynebacterium glutamicum and uses thereof

    EP2559758A1

  • Genomic engineering of the biosynthetic pathway leading to increased NADPH

    JP2020520645A

  • A microorganism of corynebacterium genus having enhanced l-lysine productivity and a method of producing l-lysine using the same

    KR100838038B1

  • Use of promoters and auxiliary genes from Corynebacterium glutamicum to regulate their expression

    KR1020200026881A

  • Microorganism Comprising Mutated LysE and Method of L-Amino Acid Production Using the Same

    KR102139806B1